Our new paper out now in Blood Reviews, on a potentially groundbreaking therapy for AL Amyloidosis, CAEL-101 sciencedirect.com/science/articl…

The remarkable story of Velcade. In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. NEJM Story in thread.

My mentor and colleague Mayo Clinic Dr. Ayalew Tefferi will be honored with the Giants of Cancer Care Award OncLive.com tomorrow. #ASCO25 Dr. Tefferi and I work together as Editors of Blood Cancer Journal He is one of the most influential and amazing educators in medicine.

Many congratulations 🎊!!

Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. ja.ma/3SVK2I2

We kicked off #ASCO25 watching Roswell Park Fellow Zunairah Shah discussing outcomes gaps for patients receiving common ADC therapies for metastatic #breastcancer — in a talk co-moderated by one Roswell Park fellowship alumna and mentored by another. 👏 Yara Abdou, MD, MSCR Shipra Gandhi

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results:

Images in Clinical Medicine: Insulin-Derived Amyloidosis nej.md/43kh7SJ #Endocrinology

Original Article: Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma (MIDAS phase 3 trial) nej.md/4mkaecR #ASCO25 | ASCO

👏 ⭐️ Roswell Park fellow Anuja Abhyankar Roswell Park Hematology/Oncology Fellowship

🎥Zunairah Shah if Roswell Park discusses real-world disparities in HER2+ mBC outcomes with ADCs: Watch here➡️ ow.ly/cgov50WekyI ⬅️ ASCO VJ Oncology #ASCO25 #BreastCancer #BCsm #HER2 #HealthEquity #ImmunoOnc

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and International Myeloma Foundation, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! Vincent Rajkumar

Big News for CAR T cell delivery to patients and monitoring: FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies #FDA #Tcellrx #immunotherapy fda.gov/vaccines-blood…

Myeloma Society educational workshop in Marrakech with Nikhil C. Munshi, MD Sagar Lonial MD Shaji Kumar Meral Beksac Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 ..excellent talks and great cases.. stay tuned for accessing the web content.

👏 I saw an interesting anecdote and just looked up the reference. Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer... these words are still true today! pubmed.ncbi.nlm.nih.gov/18750361/

Your research can inform, inspire, and ignite progress in #hematology! The abstract submission portal for the 67th ASH Annual Meeting and Exposition is OPEN. Share your advancements in science, translational research, or care disparities. Submit today: ow.ly/6WaQ50WisKY

Myeloma Drug's Comeback Nixed by FDA Panel medpagetoday.com/hematologyonco… Nitpicking over trial inclusions and posing the wrong questions (about dose instead of effectiveness) robbed #mmsm patients of an extremely effective ADC. Myeloma pts will die if FDA adheres to this sad vote.

Thrilled to see this collaborative effort from Dr. Mohammadpour's lab 👏. Great example of team science. Paired focal lesions and bone marrow analysis reveal: ➡️ 3️⃣ distinct CXCR2+ PMNs ➡️TREM1+CD10+ is associated with ⬇️ survival ➡️ Translational Trial: bit.ly/4fM5sSR

I appreciate the shout out from my brothers at Gut Onc Lab. So much work to do , and just thrilled to be able to help contribute to moving the bar forward